All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

Continued blinded-dose crofelemer treatment in the trial extension is intended to support an NDA filing in mid-2027 for microvillus inclusion disease (MVID), an ultrarare pediatric condition. The update provides a defined regulatory-development timeline but does not disclose efficacy, safety, or financial results.